<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1057">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03093116</url>
  </required_header>
  <id_info>
    <org_study_id>TPX-0005-01</org_study_id>
    <nct_id>NCT03093116</nct_id>
  </id_info>
  <brief_title>A Study of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements</brief_title>
  <acronym>TRIDENT-1</acronym>
  <official_title>A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>TP Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>TP Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1 will assess safety and tolerability of TPX-0005 via a standard dose escalation
      scheme, and determine the recommended phase 2 dose.

      Phase 2 will assess safety and efficacy of TPX-0005.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 27, 2017</start_date>
  <completion_date type="Anticipated">December 2021</completion_date>
  <primary_completion_date type="Anticipated">January 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>No masking</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Define the Maximum Tolerated Dose (MTD)</measure>
    <time_frame>Within 28 days of the first TPX-0005 dose for each patient.</time_frame>
    <description>To determine the MTD.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Define the Recommended Phase 2 Dose (RP2D)</measure>
    <time_frame>Within 28 days of the first TPX-0005 dose for each patient.</time_frame>
    <description>To determine the RP2D.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>Two to three months after starting treatment for each patient.</time_frame>
    <description>To determine the ORR of TPX-0005 as assessed by Blinded Independent Central Review.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To determine the effect of food on the AUC of TPX-0005.</measure>
    <time_frame>Two to three months after starting treatment for each patient.</time_frame>
    <description>To determine the effect of food on the AUC of TPX-0005.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the time to response (TTR)</measure>
    <time_frame>Approximately three years.</time_frame>
    <description>• To determine the TTR of TPX-0005.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the duration of response (DOR)</measure>
    <time_frame>Approximately three years.</time_frame>
    <description>• To determine the DOR of TPX-0005.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the clinical benefit rate (CBR)</measure>
    <time_frame>Approximately three years.</time_frame>
    <description>• To determine the CBR of TPX-0005.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the progression free survival (PFS).</measure>
    <time_frame>Approximately three years.</time_frame>
    <description>• To determine the PFS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the overall survival (OS).</measure>
    <time_frame>Approximately three years.</time_frame>
    <description>• To determine the OS.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the intracranial objective response rate.</measure>
    <time_frame>Approximately three years.</time_frame>
    <description>• To determine the intracranial objective response rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To determine the CNS progression-free survival.</measure>
    <time_frame>Approximately three years.</time_frame>
    <description>• To determine the CNS progression-free survival.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">450</enrollment>
  <condition>Locally Advanced Solid Tumors</condition>
  <condition>Metastatic Solid Tumors</condition>
  <condition>Non Hodgkin Lymphoma</condition>
  <arm_group>
    <arm_group_label>TPX-0005</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral TPX-0005</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oral TPX-0005</intervention_name>
    <description>Oral TPX-0005 capsules.</description>
    <arm_group_label>TPX-0005</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          1. Histologically or cytologically confirmed diagnosis of locally advanced or metastatic
             solid tumor (including non-Hodgkin Lymphoma) (Stage IV, AJCC v.7) that harbors an
             ALK, ROS1, NTRK1, NTRK2, or NTRK3 gene rearrangement by protocol specified tests.

          2. ECOG PS 0-1.

          3. Age ≥18 (or age ≥ 20 of age as required by local regulation).

          4. At least 1 measurable target lesion according to RECIST version 1.1. CNS-only
             measurable disease as defined by RECIST version 1.1 is allowed.

          5. Prior cytotoxic chemotherapy is allowed.

          6. Prior immunotherapy is allowed.

          7. Resolution of all acute toxic effects (excluding alopecia) of any prior anti-cancer
             therapy to National Cancer Institute Common Terminology Criteria for Adverse Events
             (NCI CTCAE) Version 4.03 Grade less than or equal to 1.

          8. Patients with asymptomatic CNS involvement are allowed.

          9. Life expectancy ≥ 3 months.

        Key Exclusion Criteria:

          1. Concurrent participation in another therapeutic clinical trial.

          2. Symptomatic CNS involvement.

          3. Any of the following cardiovascular history in the past 6 months: myocardial
             infarction, unstable angina, coronary/ peripheral artery bypass graft, symptomatic
             congestive heart failure, cerebrovascular accident or transient ischemic attack,
             pulmonary embolism, deep vein thrombosis, symptomatic bradycardia, requirement for
             anti-arrhythmic medication.

          4. History of prolonged QTc interval.

          5. Known active infections (bacterial, fungal, viral including HIV positivity).

          6. Gastrointestinal disease (e.g., Crohn's disease, ulcerative colitis, or short gut
             syndrome) or other malabsorption syndromes that would impact drug absorption.

          7. Peripheral neuropathy ≥ Grade 2.

          8. Known interstitial lung disease, interstitial fibrosis, or history of tyrosine kinase
             inhibitor-induced pneumonitis. Patients with a history of prior radiation pneumonitis
             are not excluded.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John KC Lim, Pharm.D.</last_name>
    <role>Study Director</role>
    <affiliation>TP Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>TP Therapeutics, Inc.</last_name>
    <phone>+1 (858) 276-0005</phone>
    <email>clinical@tptherapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>UC Irvine Health, Chao Family Comprehensive Cancer Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanna Searcy</last_name>
      <phone>877-827-8839</phone>
      <email>ucstudy@uci.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Deepa Ramaswami</last_name>
      <phone>646-888-4425</phone>
      <email>ramaswad@mskcc.org</email>
    </contact>
    <contact_backup>
      <last_name>Judy Nguyen</last_name>
      <phone>(646) 888-4425</phone>
      <email>Nguyenj2@mskcc.org</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <lastchanged_date>March 27, 2017</lastchanged_date>
  <firstreceived_date>March 6, 2017</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ALK Gene Rearrangement</keyword>
  <keyword>ROS1 Gene Rearrangement</keyword>
  <keyword>NTRK 1/2/3 Gene Rearrangement</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There are no plans to share individual participant data with other researchers.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
